InvestorsObserver
Sign Up Login

RUBY Rubius Therapeutics Inc.

$0.02 $0.00 (10.00%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

RUBY Stock Analysis Overview

What this means: Rubius Therapeutics Inc. (RUBY) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives RUBY a rank of 0. Our methodology considers analysis of the company's financial situation and how it has traded recently. RUBY rank of 0 means that it ranks below 100% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

RUBY Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

RUBY Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

RUBY Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

RUBY Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

RUBY Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

RUBY Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

RUBY Stock Analysis Overview

What this means: Rubius Therapeutics Inc. (RUBY) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives RUBY a rank of 0. Our methodology considers analysis of the company's financial situation and how it has traded recently. RUBY rank of 0 means that it ranks below 100% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full RUBY report

RUBY Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

RUBY Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

RUBY Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

RUBY Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

RUBY Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

RUBY Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Rubius Therapeutics Inc. (RUBY) Analyst Forecast

RUBY Price, Volume, Earnings, and Dividend Date

  • Last Price $0.02
  • Previous Close $0.02
  • Change $0.00
  • Open $0.02
  • Volume 1,965,899
  • Avg. Volume (100-day) 3,051,825
  • Market Cap 1,990,625
  • Days Range 0.018 - 0.0243
  • 52-week Range 0.01 - 6.18
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E 9
  • EPS —
  • Earnings Date 02/07/23
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 5.153
  • PEG Ratio —

Rubius Therapeutics Inc. (RUBY) Company Description

Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.

Rubius Therapeutics Inc. (RUBY) Stock Chart

View Interactive RUBY chart

My Watchlists

Top Stocks in Biotechnology